Drug donanemab seen as turning point in dementia fight
Drug donanemab seen as turning point in dementia fight Results out today confirm that the drug donanemab, hailed as a turning point in the fight against Alzheimer's, slows cognitive decline by about a third. Mike Colley, who is 80, is one of only a few dozen patients in the UK to take part in the global trial, now published in the journal JAMA.alzheimer'sLINK